Home Latest Articles
Latest Articles
  • Yunyan BI, Meng WU, Wen ZHANG, Lingjun KONG, Xianwei GONG
    World Clinical Drug. 2023, 44(10): 1098-1103.

    In recent years, the review and approval of rare disease drugs in China has been accelerated, and the negotiation of access to the national medical insurance drug catalogue has been fully launched. Through comparative analysis of the national conversation catalogue over the years, it can be seen that from 2017 to 2022, the number of rare disease drugs included in medical insurance through national negotiations has increased from zero to 29 year by year, the time from listing to inclusion in medical insurance has been significantly shortened, and the accessibility has been significantly improved. The list of rare diseases drugs covered 16 rare disease, including 26 (89.6%) imported enterprise products and 3 (10.4%) domestic enterprise products. It reveals that although the number of rare disease drugs listed and medical insurance coverage in China have increased, the coverage of rare diseases is still small, and the research and innovation ability of domestic pharmaceutical enterprises is relatively weak. It is suggested that medical insurance, medical treatment and medicine should continue to play a synergistic role to provide sustainable impetus for the guarantee of rare disease drug use in China.

  • Yanmei SU, Liping GU
    World Clinical Drug. 2023, 44(10): 1104-1109.

    In recent years, the complex preparation of glucagon-like peptide-1 receptor agonist (GLP-1RA) and basal insulin has attracted much attention. It has significant efficacy and good safety in patients with type 2 diabetes mellitus, which can effectively control blood glucose level, reduce body mass gain, gastrointestinal adverse reactions and the risk of cardiovascular diseases, reduce the incidence of hypoglycemia and treatment costs, and improve patient compliance. This article reviewed the research progress of GLP-1RA and basic insulin compound preparation, to clarify its mechanism and efficacy, and provide certain reference for clinical practice.

  • Xuetong WANG, Bilian KE
    World Clinical Drug. 2023, 44(10): 1110-1113.

    Low vision (LV) seriously affected the daily life of patients. The diagnosis, treatment and rehabilitation of LV are of great significance. The LV rehabilitation program should be formulated after professional evaluation, the primary disease diagnosis and treatment should be standardized, and visual or non-visual rehabilitation means should be adopted to improve the quality of life of patients. In visual rehabilitation, new head-mounted display based on virtual reality and augmented display technology have developed rapidly in recent years, which can help LV patients improve visual function and quality of life. This article reviewed the research progress of diagnosis, treatment and rehabilitation of LV in order to provide clinical reference.

  • Xiangjin GAO, Ruiping WANG
    World Clinical Drug. 2023, 44(10): 1114-1118.

    Gestational diabetes mellitus (GDM) is a metabolic disorder during pregnancy. In recent years, the prevalence rate of GDM is high and rising rapidly. GDM can cause serious harm to both mother and infant, inducing macrosomia, fetal distress, fetal anomaly, etc. It can also cause type 2 diabetes mellitus and cardiovascular diseases in the mother. Physical exercise can prevent GDM and help GDM patients control blood glucose. This article summarized the effects of physical exercise in the prevention of GDM, focused on the effects of physical exercise on blood glucose control and pregnancy outcome in GDM patients, and summarized the common exercise methods, exercise time, frequency and intensity, so as to provide a basis for more research in related fields, promote the application of physical exercise in GDM, and thus provide certain protection for maternal and child health.

  • Manman LI, Linyun ZHU, Tong WU, Haifeng ZHOU
    World Clinical Drug. 2023, 44(10): 1119-1121.

    Bronchial asthma is one of the common chronic respiratory diseases in clinic. Western medicine mainly treats with glucocorticoids and bronchodilation drugs, but there are many adverse reactions, resulting in poor patient compliance and high recurrence rate. Traditional Chinese medicine (TCM) has certain advantages in the prevention and treatment of bronchial asthma, which can reduce the hormone dependence of patients, reduce the occurrence of adverse reactions, and reduce the number of recurrence. This article reviews the etiology and treatment, syndrome differentiation and clinical research progress of TCM in the prevention and treatment of bronchial asthma, in order to provide new ideas for the prevention and treatment of bronchial asthma.

  • Wenyi RUAN, Meng ZHANG, Biao YU, Heping CAI, Xiaoling WANG, Zhigang ZHAO
    World Clinical Drug. 2023, 44(10): 1122-1132.
    Objective

    To investigate the current situation of accessibility of essential medicines for children in China, to provide reference for the establishment of children's essential medicines list and to promote the accessibility of essential medicines for children in China.

    Methods

    By comparing the "Model List of Essential Medicines for Children" issued by WHO in 2021 and the "National Essential Medicines List" issued by China in 2018, the list of essential medicines for children was screened and a questionnaire was made. From March 3 to March 20, 2022, a survey on the accessibility of 124 essential medicines was conducted in 31 children's specialized hospitals and maternal and child health hospitals across the country in the form of questionnaires. The survey included drug availability, manufacturers, prices and usage in 2021.

    Results

    Among the 124 investigated drugs, 106 drugs were available and 18 drugs were unavailable. Among the available drugs, the average availability of chemical drugs, biological products and proprietary Chinese medicines was 40.51%, 35% and 27.6%, respectively. The median price ratio (MPR) of 12 primary drugs was 7.62, and the MPR of 46 generic drugs was 1.95. The MPR of 11 drugs with both primary and generic drugs were 8.35 and 1.43, respectively. The affordability analysis of 5 essential medicines for children with asthma, nephrotic syndrome and epilepsy showed that the drug cost of 1 treatment plan was lower than the national daily minimum wage, indicating that the affordability of the 5 drugs was well affordable. For the 9 essential medicines with both primary and generic drugs, 5 primary drugs were used more frequently than generic drugs, and the other 4 drugs were used less frequently than generic drugs.

    Conclusion

    Among the 124 essential medicines, the availability of chemical drugs, biological products and proprietary Chinese medicines was low. For the essential medicines commonly used in children for asthma, epilepsy and nephrotic syndrome, generic drugs have reasonable prices and good affordability. The price of the primary drug is basically reasonable, and the affordability is weaker than that of generic drugs. The frequency of use of the primary drug was slightly higher than that of the generic drug.

  • Yeping YANG, Zhaoyun ZHANG
    World Clinical Drug. 2023, 44(9): 895-898.

    Diabetic nephropathy (DN) is the main factor leading to end-stage renal disease, but the types and effects of current therapeutic drugs are limited. Mineralocorticoid receptor antagonist (MRA) has certain renal protection effect in patients with DN, and its mechanism may be related to inhibiting inflammation, reducing renal fibrosis and improving oxidative stress imbalance. This article further summarized the effects of MRA on DN, in order to provide some reference for clinical diagnosis and treatment.

  • Yuanying XU, Xinghua CAI, Huihui ZHANG, Wenwen KONG, Wenjun SHA, Tao LEI
    World Clinical Drug. 2023, 44(9): 899-903.

    The pathogenesis of diabetic nephropathy (DN) is complex, involving metabolism, hemodynamics and inflammation. At present, the main treatment drugs for DN are renin-angiotensin system inhibitors, but not all patients can obtain satisfactory results. Glucagon-like peptide-1 receptor (GLP-1R), as a potential target for the treatment of DN, has great benefits in regulating blood glucose homeostasis and cardiovascular protection, and has a potential role in reducing the risk of renal adverse outcomes related to DN. This article reviewed the mechanism of GLP-1R as a therapeutic target for DN in alleviating disease progression, and discusses the efficacy of related preparations in clinical application.

  • Jingting WANG, Qinyi YIN, Hao LU
    World Clinical Drug. 2023, 44(9): 904-907.

    Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes mellitus and the main cause of end-stage renal disease. In recent years, traditional Chinese medicine has certain advantages in reducing proteinuria, protecting renal function and delaying the progression of DN. Clinically, DN is usually treated by syndrome differentiation and type treatment, traditional prescription and Chinese patent medicine, and the effect is remarkable. This article reviewed the recent progress of randomized controlled studies in the treatment of DN with traditional Chinese medicine in accordance with the requirements of evidence-based medicine, in order to provide some reference for its prevention and treatment.

  • Yilei CONG, Tengfei WU, Jie MIN, Yiyun ZHU, Shisi XIA, Yue YUAN, Xinyu YANG, Hua YANG
    World Clinical Drug. 2023, 44(9): 908-913.

    Sodium-glucose linked transporter-2 inhibitor (SGLT-2i) is a commonly used oral hypoglycemic agent in clinical practice, which reduces blood glucose by inhibiting renal tubule glucose reabsorption and increasing urinary glucose excretion, while increasing urinary sodium excretion. It plays the role of reducing blood pressure and reducing body mass, and treats diabetic nephropathy (DN) in multiple ways. This article briefly summarized the role, mechanism and clinical efficacy of SGLT-2i in the occurrence and development of DN, aiming to provide some reference for clinical practice.

News